Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

A European business lobby group urged China to take steps not to prioritise low prices over product safety in the country's ...

The U.S. Food and Drug Administration on Thursday made recommendations to vaccine manufacturers for the virus strains to be ...

Dr. Mehmet Oz discussed Medicaid reform, Medicare upcoding, and timely FDA drug reimbursements in his Senate confirmation hearing. Read more here.

Plus, pharmacy groups famed for opioid bankruptcies join forces and the mysterious Deutsche Bank employee making more than its CEO ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

In Thursday's meeting, the director of the FDA's Center for Drug Evaluation and Research said plans for coming layoffs were ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

FREE TO READ] Nearly all climate-themed funds focus on investments aimed at reducing emissions. That is starting to change ...

The confirmation hearing for Dr. Mehmet Oz, the former television host, comes amid a brewing fight over major cuts to ...